The Latest Breaking News from GSK

A £1 billion profits landmark for Next and strong trading at Standard Chartered today provided FTSE 100 cheer during another painful session for GSK investors.

A 5% slide in the price of Brent Crude today ensured BP and Shell led the fallers board during an otherwise resilient session for the FTSE 100 index.

About 6,000 to 10,000 people 65 and older die from RSV in the U.S. annually, the CDC says.

We can likely expect a short trip.

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading…

The CDC has clarified and narrowed its recommendations for which older adults should get an RSV vaccine.

Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

GSK stock fell early Wednesday on light sales of two key vaccines, Shingrix and Arexvy, though the company otherwise beat expectations.